{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:33:02Z","timestamp":1793622782340,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.nrleng.2026.501923","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T11:34:08Z","timestamp":1777116848000},"page":"501923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuropathic involvement in wild-type transthyretin amyloidosis"],"prefix":"10.1016","volume":"41","author":[{"given":"N.","family":"Morato-Mart\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ballesteros-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mart\u00ednez-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gal\u00e1n-D\u00e1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2026.501923_bib0185","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12875-020-01252-4","article-title":"Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner","volume":"21","author":"Gertz","year":"2020","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.nrleng.2026.501923_bib0190","doi-asserted-by":"crossref","first-page":"105313","DOI":"10.1016\/j.neuint.2022.105313","article-title":"Transthyretin: its function and amyloid formation","volume":"155","author":"Ueda","year":"2022","journal-title":"Neurochem Int"},{"key":"10.1016\/j.nrleng.2026.501923_bib0195","doi-asserted-by":"crossref","first-page":"13158","DOI":"10.3390\/ijms222313158","article-title":"A brief journey through protein misfolding in transthyretin amyloidosis (ATTR amyloidosis)","volume":"22","author":"Gonzalez-Duarte","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nrleng.2026.501923_bib0200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/biomedicines7010011","article-title":"Ultrastructure in transthyretin amyloidosis: from pathophysiology to therapeutic insights","volume":"7","author":"Koike","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.nrleng.2026.501923_bib0205","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1038\/s41467-022-33591-4","article-title":"Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis","volume":"13","author":"Steinebrei","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.nrleng.2026.501923_bib0210","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nrleng.2026.501923_bib0215","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1007\/s12350-022-02990-x","article-title":"Amyloid myopathy: expanding the clinical spectrum of transthyretin amyloidosis \u2013 case report and literature review","volume":"30","author":"Ungericht","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nrleng.2026.501923_bib0220","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13104-023-06491-z","article-title":"Targeted sequencing of selected functional genes in patients with wild-type transthyretin amyloidosis","volume":"16","author":"Moreno-G\u00e1zquez","year":"2023","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.nrleng.2026.501923_bib0225","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-med-052918-020140","article-title":"Cardiac amyloidosis: overlooked, underappreciated, and treatable","volume":"71","author":"Rubin","year":"2020","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.nrleng.2026.501923_bib0230","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijcard.2018.06.006","article-title":"Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population","volume":"270","author":"Mohamed-Salem","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.nrleng.2026.501923_bib0235","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s10741-020-10062-w","article-title":"Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis","volume":"26","author":"Bistola","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.nrleng.2026.501923_bib0240","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nrleng.2026.501923_bib0245","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nrleng.2026.501923_bib0250","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.nrleng.2026.501923_bib0255","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nrleng.2026.501923_bib0260","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40119-021-00222-w","article-title":"Multidisciplinary approaches for transthyretin amyloidosis","volume":"10","author":"Koike","year":"2021","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.nrleng.2026.501923_bib0265","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/13506129.2019.1697224","article-title":"Late-onset peripheral neuropathy in patients with wild type transthyretin amyloidosis (wtATTR)","volume":"27","author":"\u017divkovi\u0107","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.nrleng.2026.501923_bib0270","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS \u2013 The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.nrleng.2026.501923_bib0275","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/13506129.2021.2014448","article-title":"Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis","volume":"29","author":"Kleefeld","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.nrleng.2026.501923_bib0280","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1017\/cjn.2020.271","article-title":"Utility of neuropathy screening for wild-type transthyretin amyloidosis patients","volume":"48","author":"Russell","year":"2021","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.nrleng.2026.501923_bib0285","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jns.12403","article-title":"Peripheral neuropathy symptoms in wild type transthyretin amyloidosis","volume":"25","author":"Yungher","year":"2020","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.nrleng.2026.501923_bib0290","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10072-022-06459-0","article-title":"Peripheral nerve involvement in wild-type transthyretin amyloidosis","volume":"44","author":"Campagnolo","year":"2023","journal-title":"Neurol Sci"},{"key":"10.1016\/j.nrleng.2026.501923_bib0295","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/13506129.2021.1976751","article-title":"Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type","volume":"29","author":"Papagianni","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.nrleng.2026.501923_bib0300","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/13506129.2022.2043270","article-title":"Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"29","author":"Barroso","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.nrleng.2026.501923_bib0305","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40120-021-00267-y","article-title":"A descriptive analysis of ATTR amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey","volume":"10","author":"Gonz\u00e1lez-Moreno","year":"2021","journal-title":"Neurol Ther"},{"key":"10.1016\/j.nrleng.2026.501923_bib0310","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/ehf2.13131","article-title":"Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan\u00ae in transthyretin wild-type cardiac amyloidosis","volume":"8","author":"Kharoubi","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.nrleng.2026.501923_bib0315","unstructured":"cima.aemps.es [Internet]. Spain: CIMA. Available from: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/1110717003\/FT_1110717003.pdf [cited 10 March 2024]."},{"key":"10.1016\/j.nrleng.2026.501923_bib0320","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2026.501923_bib0325","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1159\/000525883","article-title":"Estimating the effect of tafamidis on cardiovascular-related hospitalization in NYHA class III patients with transthyretin amyloid cardiomyopathy in the presence of death","volume":"147","author":"Li","year":"2022","journal-title":"Cardiology"},{"key":"10.1016\/j.nrleng.2026.501923_bib0330","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.nrleng.2026.501923_bib0335","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","article-title":"Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies","author":"Van Nes","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2026.501923_bib0340","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jns5.12059","article-title":"Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy","volume":"19","author":"Vinik","year":"2014","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.nrleng.2026.501923_bib0345","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1212\/WNL.0b013e3182120147","article-title":"Assessing autonomic dysfunction in early diabetic neuropathy: the Survey of Autonomic Symptoms","volume":"76","author":"Zilliox","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2026.501923_bib0350","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.arcmed.2005.11.008","article-title":"R\u2013R interval variation and sympathetic skin response in fibromyalgia","volume":"37","author":"Ozgocmen","year":"2006","journal-title":"Arch Med Res"},{"key":"10.1016\/j.nrleng.2026.501923_bib0355","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.nrl.2018.03.001","article-title":"Valores normativos del Fototest en pacientes neurol\u00f3gicos sin deterioro cognitive","volume":"37","author":"Carnero Pardo","year":"2022","journal-title":"Neurolog\u00eda"},{"key":"10.1016\/j.nrleng.2026.501923_bib0360","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s13023-023-02962-5","article-title":"A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"18","author":"Gentile","year":"2023","journal-title":"Orphanet J Rare Dis"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580826000295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580826000295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:24:34Z","timestamp":1793622274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580826000295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2173580826000295"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.501923","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuropathic involvement in wild-type transthyretin amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.501923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501923"}}